NL300163I1 - Vermenselijkte anti-CD1 11a-antilichamen. - Google Patents

Vermenselijkte anti-CD1 11a-antilichamen.

Info

Publication number
NL300163I1
NL300163I1 NL300163C NL300163C NL300163I1 NL 300163 I1 NL300163 I1 NL 300163I1 NL 300163 C NL300163 C NL 300163C NL 300163 C NL300163 C NL 300163C NL 300163 I1 NL300163 I1 NL 300163I1
Authority
NL
Netherlands
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
NL300163C
Other languages
English (en)
Other versions
NL300163I2 (nl
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NL300163I1 publication Critical patent/NL300163I1/nl
Publication of NL300163I2 publication Critical patent/NL300163I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NL300163C 1996-11-27 2004-11-12 Vermenselijkte anti-CD1 11a-antilichamen. NL300163I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
PCT/US1997/019041 WO1998023761A1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES

Publications (2)

Publication Number Publication Date
NL300163I1 true NL300163I1 (nl) 2005-01-03
NL300163I2 NL300163I2 (nl) 2005-07-01

Family

ID=25046834

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300163C NL300163I2 (nl) 1996-11-27 2004-11-12 Vermenselijkte anti-CD1 11a-antilichamen.

Country Status (17)

Country Link
EP (2) EP1516629B1 (nl)
JP (2) JP3778945B2 (nl)
KR (1) KR100532178B1 (nl)
AR (1) AR008919A1 (nl)
AT (1) ATE267257T1 (nl)
AU (1) AU731817C (nl)
CA (1) CA2272842C (nl)
DE (3) DE122004000047I2 (nl)
DK (2) DK1516629T3 (nl)
ES (1) ES2221045T3 (nl)
FR (1) FR04C0028I2 (nl)
IL (3) IL130143A0 (nl)
LU (1) LU91122I2 (nl)
NL (1) NL300163I2 (nl)
PT (1) PT941344E (nl)
WO (1) WO1998023761A1 (nl)
ZA (1) ZA979599B (nl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
DE60042735D1 (de) * 1999-03-19 2009-09-24 Genentech Inc Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
AU768324B2 (en) * 1999-12-14 2003-12-11 Genentech Inc. TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
AU2001287000A1 (en) * 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
ES2368737T3 (es) * 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
AU2004265253B2 (en) 2003-07-28 2011-09-01 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
US7927591B2 (en) * 2004-02-19 2011-04-19 The Cbr Institute For Biomedical Research, Inc. Conformation specific antibodies
CA2568570A1 (en) * 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
EP2120915B1 (en) 2007-01-22 2011-09-28 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
SI2848625T1 (sl) 2008-08-14 2019-11-29 Genentech Inc Postopki za odstranjevanje kontaminanta z uporabo ionskoizmenjevalne membranske kromatografije z izpodrinjenjem nativnega proteina
EP2334323A2 (en) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
CN105037535A (zh) 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
CA2752884A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
EP2499240A1 (en) 2009-11-12 2012-09-19 Vbi Technologies, LLC Subpopulations of spore-like cells and uses thereof
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
ES2722201T3 (es) 2010-03-22 2019-08-08 Hoffmann La Roche Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP3597671B1 (en) 2010-05-17 2022-09-21 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
ES2599412T3 (es) 2010-05-28 2017-02-01 F. Hoffmann-La Roche Ag Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
EP2603525A1 (en) 2010-08-13 2013-06-19 F.Hoffmann-La Roche Ag Antibodies to il-1beta and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
BR112014015101A8 (pt) 2011-12-22 2021-06-08 Genentech Inc métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
MX365947B (es) 2012-03-27 2019-06-19 Genentech Inc Operaciones de cosecha mejoradas para proteinas recombinadas.
CA2873646C (en) 2012-05-18 2022-04-26 Genentech, Inc. High-concentration monoclonal antibody formulations
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
SG10201710758PA (en) 2013-07-09 2018-02-27 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
PT3021869T (pt) 2013-07-16 2020-09-10 Hoffmann La Roche Métodos de tratamento do cancro com antagonistas da ligação ao eixo pd-1 e inibidores do tigit
KR102355306B1 (ko) 2014-07-09 2022-01-24 제넨테크, 인크. 세포 은행의 해동 회수를 개선하는 ph 조정
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
CA2997130A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
RU2732591C2 (ru) 2015-09-25 2020-09-21 Дженентек, Инк. Анти-tigit антитела и способы применения
BR112018010360A2 (pt) 2015-11-24 2018-12-04 Annexon Inc fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
AU2017242031B2 (en) 2016-03-29 2023-07-27 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
AU2017382281A1 (en) 2016-12-22 2019-06-13 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020025623A2 (pt) 2018-07-03 2021-03-23 Bristol-Myers Squibb Company métodos de produção de proteínas recombinantes
EP3864127A1 (en) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Method for membrane gas transfer in high density bioreactor culture
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
WO2020210440A1 (en) 2019-04-12 2020-10-15 Geltor, Inc. Recombinant elastin and production thereof
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
DE69729209D1 (de) 2004-06-24
NL300163I2 (nl) 2005-07-01
DE69729209T2 (de) 2005-05-19
EP1516629A3 (en) 2006-09-27
AU4992997A (en) 1998-06-22
DE122004000047I1 (de) 2005-04-21
ES2221045T3 (es) 2004-12-16
AR008919A1 (es) 2000-02-23
ATE267257T1 (de) 2004-06-15
AU731817C (en) 2001-11-01
ZA979599B (en) 1999-04-28
EP0941344A1 (en) 1999-09-15
LU91122I2 (fr) 2005-01-10
WO1998023761A1 (en) 1998-06-04
JP3778945B2 (ja) 2006-05-24
DK0941344T3 (da) 2004-09-27
CA2272842C (en) 2012-05-15
FR04C0028I2 (nl) 2007-10-26
FR04C0028I1 (nl) 2005-02-11
DK1516629T3 (da) 2013-06-03
PT941344E (pt) 2004-10-29
JP2001505425A (ja) 2001-04-24
EP1516629A2 (en) 2005-03-23
KR100532178B1 (ko) 2005-12-01
IL130143A0 (en) 2000-06-01
JP4309383B2 (ja) 2009-08-05
IL175583A0 (en) 2006-09-05
EP0941344B1 (en) 2004-05-19
KR20000069147A (ko) 2000-11-25
DE122004000047I2 (de) 2006-06-14
IL130143A (en) 2006-08-01
CA2272842A1 (en) 1998-06-04
AU731817B2 (en) 2001-04-05
EP1516629B1 (en) 2013-04-03
JP2006036779A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
NL300163I1 (nl) Vermenselijkte anti-CD1 11a-antilichamen.
NO955167D0 (no) Monoklonalt anti-
BR9507275A (pt) 1h-3-aril-pirrolidina-2,4-dionas alcoxi-alquil-substituídas
DE69636353D1 (de) Datenübetragungsvorrichtung.
NL1004863A1 (nl) 5-Amino-4-ethylsulfinyl-1-arylpyrazolen.
TR199800517A3 (tr) Hümanize anti-hümen fas antikor.
TR199800604A3 (tr) Anti-fas antikorlari.
TR199501542A2 (tr) Bagisiklik önleyici aktiviteye sahip monoklonal antikor parcalari.
NL1000612C2 (nl) Treden.
BR1100555B1 (pt) anticorpos monoclonais humanizados.
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
IT234659Y1 (it) Sottosella.
FR2720962B1 (fr) Baguetteuse.
FR2720961B1 (fr) Baguetteuse.
FR2714950B3 (fr) Réducteur-variateur.
ES1031423Y (es) Apoyacabezas.
TR199501236A2 (tr) Halka bicimindeki birarada tutma vasitasi.
NL1002217A1 (nl) Asymmetrische cirkelzaag.
IT1280484B1 (it) Trecciatrice.
BR1100504A (pt) anticorpos anti-ige.
ES1032636Y (es) Osario.
ES1029950Y (es) Interruptor-conmutador.
IT239292Y1 (it) Volter.
IT240242Y1 (it) Pentola-colapasta-zuppiera.
ES1030500Y (es) Braga-compresa monouso.